Additionally, molecular diagnosis of ESR1 <1.0 % from diagnostic samples require highly sensitive technical platforms (dPCRs and NGS) that allow to identify low abundant alterations electing ER+/HER2- BC patients for oral SERD [34,35]. This evidence concerns the gene ESR1 and breast cancer.